102 related articles for article (PubMed ID: 31673702)
1. Fitting Marginal Structural and G-Estimation Models Under Complex Treatment Patterns: Investigating the Association Between De Novo Vitamin D Supplement Use After Breast Cancer Diagnosis and All-Cause Mortality Using Linked Pharmacy Claim and Registry Data.
Madden JM; Leacy FP; Zgaga L; Bennett K
Am J Epidemiol; 2020 Mar; 189(3):224-234. PubMed ID: 31673702
[TBL] [Abstract][Full Text] [Related]
2. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
Madden JM; Murphy L; Zgaga L; Bennett K
Breast Cancer Res Treat; 2018 Nov; 172(1):179-190. PubMed ID: 30039288
[TBL] [Abstract][Full Text] [Related]
3. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study.
Tentori F; Albert JM; Young EW; Blayney MJ; Robinson BM; Pisoni RL; Akiba T; Greenwood RN; Kimata N; Levin NW; Piera LM; Saran R; Wolfe RA; Port FK
Nephrol Dial Transplant; 2009 Mar; 24(3):963-72. PubMed ID: 19028748
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
[TBL] [Abstract][Full Text] [Related]
5. Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: A repeated cross-sectional study.
Madden JM; Duffy MJ; Zgaga L; Bennett K
PLoS One; 2018; 13(12):e0209033. PubMed ID: 30543699
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.
Korde LA; Doody DR; Hsu L; Porter PL; Malone KE
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):165-173. PubMed ID: 29254937
[No Abstract] [Full Text] [Related]
7. De Novo Post-Diagnosis Aspirin Use and Mortality in Women with Stage I-III Breast Cancer.
Barron TI; Murphy LM; Brown C; Bennett K; Visvanathan K; Sharp L
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):898-904. PubMed ID: 25791705
[TBL] [Abstract][Full Text] [Related]
8. Estimating the effects of time-varying treatments: incidence of fractures among postmenopausal Japanese women.
Tanaka S; Matsuyama Y; Shiraki M; Ohashi Y
Epidemiology; 2007 Sep; 18(5):529-36. PubMed ID: 17700241
[TBL] [Abstract][Full Text] [Related]
9. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
11. Adjusting for time-varying confounders in survival analysis using structural nested cumulative survival time models.
Seaman S; Dukes O; Keogh R; Vansteelandt S
Biometrics; 2020 Jun; 76(2):472-483. PubMed ID: 31562652
[TBL] [Abstract][Full Text] [Related]
12. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
15. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.
Degli Esposti L; Girardi A; Saragoni S; Sella S; Andretta M; Rossini M; Giannini S;
Endocrine; 2019 May; 64(2):367-377. PubMed ID: 30515678
[TBL] [Abstract][Full Text] [Related]
16. The relationship of vitamin D status to risk of cardiovascular disease and mortality.
Skaaby T
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634511
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
18. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
[TBL] [Abstract][Full Text] [Related]
19. A comparison of methods to estimate the hazard ratio under conditions of time-varying confounding and nonpositivity.
Naimi AI; Cole SR; Westreich DJ; Richardson DB
Epidemiology; 2011 Sep; 22(5):718-23. PubMed ID: 21747286
[TBL] [Abstract][Full Text] [Related]
20. Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.
Smith A; Murphy L; Zgaga L; Barron TI; Bennett K
Br J Cancer; 2017 Aug; 117(4):588-596. PubMed ID: 28720842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
